Product Overview

Macao-625 Tablet

Macoa 625 combines Amoxycillin (500mg) with Clavulanic Acid (125mg) to create a rational, broad-spectrum antibacterial treatment. By adding Clavulanic Acid to overcome bacterial resistance caused by beta-lactamase enzymes, this combination scores over standalone Amoxycillin through superior tissue penetration, a broader spectrum of action, and an enhanced clinical response. Supported by clinical perspectives in major medical literature—including the BMJ, Thorax Journal, and Journal of Chemotherapy—Macoa 625 offers reliable therapeutic coverage across a wide range of conditions. It is indicated for upper and lower respiratory tract infections, dental infections, skin and soft tissue infections, head and neck infections, otitis media, and uncomplicated urinary tract infections.